Litigation
Jun. 28, 2006
Medical Journal Runs Correction on Study of Vioxx Data
LOS ANGELES - On the eve of the first California Vioxx trial, the drug's manufacturer was dealt a potentially devastating blow: a medical journal corrected a key study, saying Merck & Co. provided statistical data that erroneously led to t
Daily Journal Staff Writer
LOS ANGELES - On the eve of the first California Vioxx trial, the drug's manufacturer was dealt a potentially devastating blow: a medical journal corrected a key study, saying Merck & Co. provided statistical data that erroneously led to the conclusion that the painkiller did not increase the risk of strokes or heart attacks for at least 18 months.
&nb...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In